Name | Title | Contact Details |
---|
Innoviant, Inc. is a Wausau, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
KeySource Medical, Inc. (KMI) has been supplying the generic pharmaceutical needs of retail pharmacies across the United States since 1996. Our sales force is focused on serving the interests of our customers, emphasizing the highest level of service, integrity and value. As a trusted wholesale distributor of generic pharmaceuticals, we take our responsibility to safeguard the integrity of the pharmaceutical supply chain seriously, securing it against counterfeit or adulterated products. • KeySource purchases ALL products it sells directly from FDA approved manufacturers. • KeySource has received VAWD (Verified-Accredited Wholesale Distributor) accreditation from the National Association of Boards of Pharmacy. • KeySource is an active member of HDMA (Healthcare Distribution Management Association), a National Association comprised of America`s largest pharmaceutical distributors KMI has been recognized by “INC. Magazine” as one of America`s fastest growing, privately-held companies, placing #162 on the “INC. 500” list in 2006. In 2009, KMI was a finalist and category winner in the “Fast 55” competition sponsored by the Cincinnati Business Courier. KeySource Medical is committed to serving the community through the Dennis J. Engel Giving Program. We help make it possible to serve the uninsured and those in need with prescriptions at no cost through The St. Vincent de Paul Charitable Pharmacy.
TYRX is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biochemics Inc is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
We are a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by ear, nose and throat (ENT) and allergy specialists. Our first commercial product, XHANCE® (fluticasone propionate) nasal spray, 93 microgram (mcg), is a therapeutic utilizing our proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps and, if approved, chronic rhinosinusitis without nasal polyps (also known as chronic sinusitis). In September 2017, the U.S. Food and Drug Administration (FDA) approved XHANCE for the treatment of nasal polyps in patients 18 years of age or older. XHANCE was made widely available through commercial channels in April 2018. We have initiated two Phase 3b clinical trials of XHANCE for a follow-on indication for the treatment of chronic sinusitis and expect top-line results by the end of 2021 from one trial and in the first half of 2022 from the second trial. If successful, we believe XHANCE would be the first drug therapy product approved by the FDA for the treatment of chronic sinusitis. As of February 28, 2021, we had a total of 204 full-time employees and three part-time employees. A majority of our employees are field-based, in customer-facing roles. Culture is a critical element in the management of our organization. Our talented employees, known as colleagues, are focused on driving our business with the Optinose values as the foundation for all our efforts. Our goal is that each colleague feels a deep connection to what they do, loves coming to work and is aligned to our One Mission – to improve lives. Our values of Authenticity, Fearless Conversations, Friendship, Openness, Perseverance and Possibility Thinking guide our actions and decisions.